F-group (family)
237.1.1.1 PARP
Ligands and drugs
1,081
Member domains
874
with ligand contacts (≤ 4 Å)
80.9% of members
773
with DrugDomain annotations
71.5% of members
508
with a DrugBank compound
47.0% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 237.1.1.1 belongs to X-group 237 ADP-ribosylation, which binds 8.9 ligand superclasses per 20 proteins, broader than 78% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB09074 | 09L | Olaparib | 16 |
| DB11760 | 2YQ | Talazoparib | 16 |
| DB07232 | 78P | Veliparib | 13 |
| DB11793 | 3JD | Niraparib | 12 |
| DB08348 | P34 | N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE | 11 |
| DB12332 | RPB | Rucaparib | 9 |
| DB03509 | CNQ | 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide | 8 |
| DB02054 | GAB | Gabaculine | 7 |
| DB02690 | NU1 | NU1025 | 6 |
| DB02701 | NCA | Nicotinamide | 6 |
| DB13877 | 33E | Iniparib | 6 |
| DB07677 | DRL | 2-methyl-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one | 5 |
| DB02498 | CNA | Carba-nicotinamide-adenine-dinucleotide | 4 |
| DB03072 | FRM | 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone | 2 |
| DB03073 | 3MB | 3-Methoxybenzamide | 2 |
| DB03722 | DHQ | 3,4-Dihydro-5-Methyl-Isoquinolinone | 2 |
| DB04010 | BZC | 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide | 2 |
| DB04429 | DFL | 4'-Hydroxyflavanone | 2 |
| DB07096 | 4AN | 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE | 2 |
| DB07787 | FRQ | 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ZNmetal | ZINC ION | 453 |
| UHB | 2-[4-[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]carbonylpiperazin-1-yl]-N-(1-oxidanylidene-2,3-dihydroisoindol-4-yl)ethanamide | 26 |
| 3AB | 3-aminobenzamide | 20 |
| CL | CHLORIDE ION | 20 |
| 09L | 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one | 17 |
| 2YQ | (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one | 16 |
| 3JD | 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide | 13 |
| 78P | (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium | 13 |
| DQV | [(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl [(2R,3S,4R,5S)-5-(3-carbamoylphenyl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl dihydrogen diphosphate (non-preferred name) | 13 |
| P34 | N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE | 11 |
| A1JHC | 6-[(3-chlorophenyl)methoxy]-2,3-dihydrophthalazine-1,4-dione | 9 |
| NAmetal | SODIUM ION | 9 |
| RPB | Rucaparib | 9 |
| 92R | 3-{4-[(dimethylamino)methyl]phenyl}-5-methoxyisoquinolin-1(2H)-one | 8 |
| CNQ | 3-(4-CHLOROPHENYL)QUINOXALINE-5-CARBOXAMIDE | 8 |
| YFG | 7-(cyclopentylamino)-5-fluoro-2-{[(trans-4-hydroxycyclohexyl)sulfanyl]methyl}quinazolin-4(3H)-one | 8 |
| GAB | 3-AMINOBENZOIC ACID | 7 |
| DS9 | (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one | 6 |
| G18 | 4H-thieno[2,3-c]isoquinolin-5-one | 6 |
| NCA | NICOTINAMIDE | 6 |